ArticleBMJ (Clinical research ed.)2013
Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink.
Article in BMJ (Clinical research ed.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2021Pooled it
- Association between oral fluoroquinolones and seizures: A self-controlled case series study.Neurology · 2016Pooled it
- Pooled it
- Anti-obesity medications impacting the eye: An emerging concern - a narrative review.World journal of methodology · 2026Review
- Drug-Induced Orthostatic Hypotension in UK Primary Care: A Self-Controlled Case Series Study.Clinical epidemiology · 2026Article
- Orlistat: a comprehensive review of a lipase inhibitor from obesity management to emerging oncological applications.Frontiers in pharmacology · 2026Review
- Severe hepatotoxicity associated with orlistat: clinical presentation, risk factors and outcomes.Frontiers in pharmacology · 2026Article
- [The history of the pharmacotherapy of obesity].Problemy endokrinologii · 2025Review
- Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions.International journal of obesity (2005) · 2025Review
- Article
- Does the mental health system provide effective coverage to people with schizophrenic disorder? A self-controlled case series study in Italy.Social psychiatry and psychiatric epidemiology · 2022Article
- A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT).PloS one · 2022Article
- Effects of Ethanol Extracts fromMarine drugs · 2021Article
- Data on Adiponectin from 2010 to 2020: Therapeutic Target and Prognostic Factor for Liver Diseases?International journal of molecular sciences · 2020Review
- Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes.Diabetes, obesity & metabolism · 2020Review
- Article
- Tools for causality assessment in drug-induced liver disease.Current opinion in gastroenterology · 2019Review
- The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE).BMJ (Clinical research ed.) · 2018Article
- Novel Approaches to Causality Adjudication in Drug-Induced Liver Disease.Current hepatology reports · 2018Article
- Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo measure the association between orlistat and acute liver injury.
designSelf controlled case series study.
settingPopulation based primary care setting, United Kingdom.
participants94,695 patients receiving orlistat and registered in the UK Clinical Practice Research Datalink and linked with Hospital Episode Statistics data between 1999 and 2011.
main outcome measureRelative incidence of acute liver injury comparing periods when patients were receiving orlistat with periods of non-usage.
resultsAmong 94,695 patients who received orlistat, 988 cases of acute liver injury were identified, with 335 confirmed as definite cases and 653 as probable cases. For all cases an increased incidence of liver injury was detected during the 90 day period before orlistat was first started, with an incidence rate ratio of 1.50 (95% confidence interval 1.10 to 2.06). The incidence remained raised during the first 30 days of treatment (2.21, 1.43 to 3.42), before returning to baseline levels with prolonged treatment. When the risk during the first 90 days of treatment was compared with the 90 days preceding first treatment, the incidence of liver injury was not increased (1.02, 0.67 to 1.56). An analysis restricted to definite cases showed no evidence of an increased risk of liver injury during treatment.
conclusionThe incidence of acute liver injury was higher in the periods both immediately before and immediately after the start of orlistat treatment. This suggests that the observed increased risks of liver injury linked to the start of treatment may reflect changes in health status associated with the decision to begin treatment rather than any causal effect of the drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.